FindTrial
Sign In

OriCAR-017

BIOLOGICAL2 trials

Sponsors

OriCell Therapeutics Co., Ltd.

Conditions

Blood Protein DisordersCardiovascular DiseasesHematologic DiseasesHemorrhagic DisordersHemostatic DisordersImmune System DiseasesImmunoproliferative DisordersLymphoproliferative Disorders

Phase 1

OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM
RecruitingNCT06182696
OriCell Therapeutics Co., Ltd.Relapsed and/or Refractory Multiple Myeloma
Start: 2023-10-26End: 2028-08-31Target: 83Updated: 2024-05-31
A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study
RecruitingNCT06271252
OriCell Therapeutics Co., Ltd.Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases +11
Start: 2024-04-03End: 2028-04-12Target: 81Updated: 2024-08-02